Log in

NASDAQ:DRTX - Durata Therapeutics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Durata Therapeutics, Inc is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:DRTX
CUSIP26658A10
WebN/A
Phone+1-312-2197000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive DRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for DRTX and its competitors with MarketBeat's FREE daily newsletter.


Durata Therapeutics (NASDAQ:DRTX) Frequently Asked Questions

What is Durata Therapeutics' stock symbol?

Durata Therapeutics trades on the NASDAQ under the ticker symbol "DRTX."

Has Durata Therapeutics been receiving favorable news coverage?

Media coverage about DRTX stock has trended extremely negative on Sunday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Durata Therapeutics earned a coverage optimism score of -4.5 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Durata Therapeutics.

Who are some of Durata Therapeutics' key competitors?

What other stocks do shareholders of Durata Therapeutics own?

How can I contact Durata Therapeutics?

Durata Therapeutics' mailing address is 200 S Wacker Dr Ste 2550, CHICAGO, IL 60606-5811, United States. The biotechnology company can be reached via phone at +1-312-2197000.


MarketBeat Community Rating for Durata Therapeutics (NASDAQ DRTX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  257
MarketBeat's community ratings are surveys of what our community members think about Durata Therapeutics and other stocks. Vote "Outperform" if you believe DRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/26/2020 by MarketBeat.com Staff

Featured Article: Derivative

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel